236 related articles for article (PubMed ID: 10591869)
1. Altered neuroendocrine and behavioral responses to m-chlorophenylpiperazine in 3,4-methylenedioxymethamphetamine (MDMA) users.
McCann UD; Eligulashvili V; Mertl M; Murphy DL; Ricaurte GA
Psychopharmacology (Berl); 1999 Nov; 147(1):56-65. PubMed ID: 10591869
[TBL] [Abstract][Full Text] [Related]
2. Altered prolactin response to M-chlorophenylpiperazine in monkeys previously treated with 3,4-methylenedioxymethamphetamine (MDMA) or fenfluramine.
Hatzidimitriou G; Tsai EH; McCann UD; Ricaurte GA
Synapse; 2002 Apr; 44(1):51-7. PubMed ID: 11842446
[TBL] [Abstract][Full Text] [Related]
3. (+/-)3,4-Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: clinical studies.
McCann UD; Eligulashvili V; Ricaurte GA
Neuropsychobiology; 2000; 42(1):11-6. PubMed ID: 10867551
[TBL] [Abstract][Full Text] [Related]
4. The effect of catecholamine depletion by alpha-methyl-para-tyrosine on measures of cognitive performance and sleep in abstinent MDMA users.
McCann UD; Peterson SC; Ricaurte GA
Neuropsychopharmacology; 2007 Aug; 32(8):1695-706. PubMed ID: 17203011
[TBL] [Abstract][Full Text] [Related]
5. Serotonin dysfunction in pathological gamblers: increased prolactin response to oral m-CPP versus placebo.
Pallanti S; Bernardi S; Quercioli L; DeCaria C; Hollander E
CNS Spectr; 2006 Dec; 11(12):956-64. PubMed ID: 17146409
[TBL] [Abstract][Full Text] [Related]
6. Altered response to tryptophan supplementation after long-term abstention from MDMA (ecstasy) is highly correlated with human memory function.
Curran HV; Verheyden SL
Psychopharmacology (Berl); 2003 Aug; 169(1):91-103. PubMed ID: 12759801
[TBL] [Abstract][Full Text] [Related]
7. Effect of aerobic exercise on behavioral and neuroendocrine responses to meta-chlorophenylpiperazine and to ipsapirone in untrained healthy subjects.
Broocks A; Meyer T; Gleiter CH; Hillmer-Vogel U; George A; Bartmann U; Bandelow B
Psychopharmacology (Berl); 2001 May; 155(3):234-41. PubMed ID: 11432685
[TBL] [Abstract][Full Text] [Related]
8. Neuroendocrine and mood responses to intravenous L-tryptophan in 3,4-methylenedioxymethamphetamine (MDMA) users. Preliminary observations.
Price LH; Ricaurte GA; Krystal JH; Heninger GR
Arch Gen Psychiatry; 1989 Jan; 46(1):20-2. PubMed ID: 2562914
[TBL] [Abstract][Full Text] [Related]
9. [MDMA (ecstasy): neuroendocrine and behavioral features].
Gerra G; Zaimovic A; Moi G; Laviola G; Macchia T
Ann Ist Super Sanita; 2002; 38(3):271-7. PubMed ID: 12645178
[TBL] [Abstract][Full Text] [Related]
10. Long-lasting effects of (+/-)3,4-methylenedioxymethamphetamine (ecstasy) on serotonin system function in humans.
Gerra G; Zaimovic A; Ferri M; Zambelli U; Timpano M; Neri E; Marzocchi GF; Delsignore R; Brambilla F
Biol Psychiatry; 2000 Jan; 47(2):127-36. PubMed ID: 10664829
[TBL] [Abstract][Full Text] [Related]
11. Chronic treatment with a serotonin(2) receptor (5-HT(2)R) agonist modulates the behavioral and cellular response to (+)-3,4-methylenedioxymethamphetamine [(+)-MDMA].
Ross JD; Herin DV; Frankel PS; Thomas ML; Cunningham KA
Drug Alcohol Depend; 2006 Feb; 81(2):117-27. PubMed ID: 16054778
[TBL] [Abstract][Full Text] [Related]
12. Neuroendocrine and subjective responses to pharmacological challenge with citalopram: a controlled study in male and female ecstasy/MDMA users.
Allott K; Canny BK; Broadbear JH; Stepto NK; Murphy B; Redman J
J Psychopharmacol; 2009 Sep; 23(7):759-74. PubMed ID: 18562414
[TBL] [Abstract][Full Text] [Related]
13. Reduced social interaction following 3,4-methylenedioxymethamphetamine is not associated with enhanced 5-HT 2C receptor responsivity.
Bull EJ; Hutson PH; Fone KC
Neuropharmacology; 2003 Mar; 44(4):439-48. PubMed ID: 12646281
[TBL] [Abstract][Full Text] [Related]
14. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective.
Thomasius R; Zapletalova P; Petersen K; Buchert R; Andresen B; Wartberg L; Nebeling B; Schmoldt A
J Psychopharmacol; 2006 Mar; 20(2):211-25. PubMed ID: 16510479
[TBL] [Abstract][Full Text] [Related]
15. Neuroendocrine effects of M-chlorophenylpiperazine, a serotonin agonist, in humans.
Mueller EA; Murphy DL; Sunderland T
J Clin Endocrinol Metab; 1985 Dec; 61(6):1179-84. PubMed ID: 4055985
[TBL] [Abstract][Full Text] [Related]
16. Behavioral, physiological and neuroendocrine responses in healthy volunteers to m-chlorophenylpiperazine (m-CPP) with and without ondansetron pretreatment.
Broocks A; Briggs NC; Pigott TA; Hill JL; Canter SK; Tolliver TJ; Baldemore D; Murphy DL
Psychopharmacology (Berl); 1997 Mar; 130(2):91-103. PubMed ID: 9106905
[TBL] [Abstract][Full Text] [Related]
17. Decreased pain tolerance and mood in recreational users of MDMA.
O'Regan MC; Clow A
Psychopharmacology (Berl); 2004 May; 173(3-4):446-51. PubMed ID: 14752588
[TBL] [Abstract][Full Text] [Related]
18. m-Chlorophenylpiperazine challenge in borderline personality disorder: relationship of neuroendocrine response, behavioral response, and clinical measures.
Stein DJ; Hollander E; DeCaria CM; Simeon D; Cohen L; Aronowitz B
Biol Psychiatry; 1996 Sep; 40(6):508-13. PubMed ID: 8879471
[TBL] [Abstract][Full Text] [Related]
19. Serotonin neurotoxicity after (+/-)3,4-methylenedioxymethamphetamine (MDMA; "Ecstasy"): a controlled study in humans.
McCann UD; Ridenour A; Shaham Y; Ricaurte GA
Neuropsychopharmacology; 1994 Apr; 10(2):129-38. PubMed ID: 7517677
[TBL] [Abstract][Full Text] [Related]
20. Comparative anxiogenic, neuroendocrine, and other physiologic effects of m-chlorophenylpiperazine given intravenously or orally to healthy volunteers.
Murphy DL; Mueller EA; Hill JL; Tolliver TJ; Jacobsen FM
Psychopharmacology (Berl); 1989; 98(2):275-82. PubMed ID: 2502799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
